19043 research outputs found
Sort by
Pre-Service Teachers\u27 Preparation for Teaching Online: Past Practices and Future Needs
No full textCryptosporidiosis in Individuals with Inflammatory Bowel Disease: A Scoping Review Protocol
No full textClinical Need for Point-of-Care Testing for Diabetes in Clinical and Laboratory Improvement Amendments–Waived Settings
No full text
Impact of a 30-Second Consultation on Acetaminophen Knowledge Among Middle Eastern Americans
No full textFall 2024 SOM Alumni Connections
Get PDFNYMC to Celebrate Visionary Public Health Leaders at Annual Founder’s Dinner Teeing Off for Tomorrow’s Scholars at the Golf Outing College Announces New Leadership Appointments School of Medicine Class of 2028 Marks Start of Medical School Journey Funding Will Bolster Medical School Success for Historically Disadvantaged Students NYMC Forms Academic Affiliation with Mount Sinai Medical Center in Miami Beach NYMC Research Well Represented at Touro Research Day Scarring Persists in Patients with COVID-19 Vaccine-Associated Myocarditis Study Suggests Diagnostic Surgery Can Be Used Safely on Children with Epilepsy COVID-19 Symptoms During the Omicron Surge Differ Between Boosted and Vaccinated Non-Boosted Individuals Palliative Medicine Education Provides Essential Knowledge Entries for Love at NYMC Faculty Spotlight: Srihari S. Naidu, M.D., Raises Awareness About HCM Through New Children\u27s Book Student Spotlight: Medical Student and Aspiring Entrepreneur: Nadia Ambarsom Pursues Dual Dreams Student Spotlight: SOM Student David Zuckerman Awarded AMA Physicians of Tomorrow Scholarship Alumni Spotlight: NYMC Student Recognized with Prestigious U.S. Public Health Awardhttps://touroscholar.touro.edu/nymc_som/1021/thumbnail.jp
InTouch Week of March 11, 2024
Get PDFDr. Kenneth Knapp Named Chair of Department of Public Health Dr. Mitchell Cairo Secures $2.6M FDA Grant for Infant CMV Infection Research Department of Radiation Medicine Enrolls First Patient in Nation in Prostate Cancer Clinical Trial NYMC and Regeneron Debut Neighborhood Science Seminar Series NYMC Annual Days of Giving Set for March 26 and 27 LCME Element of the Week Department Spotlight: The Office of Academic Excellence Elevates Student Achievement Dr.P.H. Candidate Advocates for Long Term Care Through the Mediahttps://touroscholar.touro.edu/in_touch/1318/thumbnail.jp
Tachy-Brady Syndrome: Electrophysiology and Evolving Principles of Management
No full textSudden alterations in the heart rate may be associated with diverse symptoms. Sinus node dysfunction (SND), also known as sick sinus syndrome, is a sinoatrial (SA) node disorder. SND is primarily caused by the dysfunction of the pacemaker, as well as impaired impulse transmission resulting in a multitude of abnormalities in the heart rhythms, such as bradycardia-tachycardia, atrial bradyarrhythmias, and atrial tachyarrhythmias. The transition from bradycardia to tachycardia is generally referred to as tachy-brady syndrome (TBS). Although TBS is etiologically variable, the manifestations remain consistent throughout. Abnormal heart rhythms have the propensity to limit tissue perfusion resulting in palpitations, fatigue, lightheadedness, presyncope, and syncope. In this review, we examine the physiology of tachy-brady syndrome, the practical approach to its diagnosis and management, and the role of adenosine in treating SND
InTouch Week of April 15, 2024
Get PDFNYMC Hosts 10th Annual Drs. Gabor and Harriette Kaley Endowed Lecture NYMC Hosts Stellar Partial Solar Eclipse Watch Party Student Spotlights: Ashley Chory\u27s Path to Global Adolescent Health Student Spotlights: Miriam Katz, M.P.H., Shares Her Research on Digital Hypertension Management Toolshttps://touroscholar.touro.edu/in_touch/1323/thumbnail.jp
Efficacy of Hp-3070, a Once-Daily Asenapine Transdermal System, in the Treatment of Adults With Schizophrenia: A Panss Five-Factor Analysis
No full textINTRODUCTION: HP-3070, a once-daily asenapine transdermal system, is the first antipsychotic patch formulation FDA approved for adults with schizophrenia. Positive and Negative Syndrome Scale (PANSS) score items can be grouped into a five-factor structure to describe specific schizophrenia symptom domains. This post hoc analysis of data from a pivotal study evaluated HP-3070\u27s efficacy by examining these factors. METHODS: In a phase 3 study, adults with an acute exacerbation of schizophrenia were randomized to six weeks of treatment with HP-3070 3.8mg/24h, 7.6mg/24h, or placebo. An analysis was performed using the five PANSS factor domains (negative symptoms, positive symptoms, disorganized thought, uncontrolled hostility/excitement, anxiety/depression). Mixed-model repeated-measures (MMRM) analysis included change from baseline (CFB) in PANSS factor score as the repeated dependent variable, with country, treatment, visit, treatment by visit interaction, and baseline PANSS score as covariates. RESULTS: The analysis included 607 patients. Treatment with HP-3070 3.8mg/24h resulted in a statistically significant LS mean CFB (improvement) vs placebo at Weeks 4-6 for all domains except for anxiety/depression, where a numerical difference was observed in favor of active treatments. Among the domains, the positive symptom factor demonstrated the numerically greatest LS mean (SE) difference from placebo in CFB, which for HP-3070 7.6mg/24h was -2.0 [0.57] and for HP-3070 3.8mg/24h was -2.3 [0.57]; \u3c0.001 for both. Treatment effect size for the positive symptom factor using Cohen\u27s (95% confidence intervals) was 0.39 (0.17, 0.61) for HP-3070 7.6mg/24h and 0.45 (0.20, 0.64) for HP-3070 3.8mg/24h. DISCUSSION: Post hoc analysis using a PANSS five-factor model suggests that HP-3070 may address a broad range of symptoms in people with schizophrenia